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Abstract
Background and Aims
Chronic kidney disease (CKD) and diabetes mellitus (DM) are considered as risk factors for
cardiovascular diseases. The purpose of this study was to clarify the relationship of CKD
and DM with the presence of abdominal aortic aneurysm (AAA).
Methods
We enrolled 261 patients with AAA (AAA+) and age-and-sex matched 261 patients without
AAA (AAA-) at two hospitals between 2008 and 2014, and examined the association
between the risk factors and the presence of AAA. Furthermore, in order to investigate the
prevalence of AAA in each group, we enrolled 1126 patients with CKD and 400 patients
with DM.
Results
The presence of CKD in patients with AAA+ was significantly higher than that in patients
with AAA- (AAA+; 65%, AAA-; 52%, P = 0.004). The presence of DM in patients with AAA+
was significantly lower than that in patients with AAA- (AAA+; 17%, AAA-; 35%, P < 0.001).
A multivariate logistic regression analysis demonstrated that hypertension, ischemic heart
disease and CKD were independent determinants, whereas, DM was a negatively indepen-
dent determinant, for the presence of AAA. The prevalence of AAA in patients with CKD 65
years old and above was 5.1%, whereas, that in patients with DM 65 years old and above
was only 0.6%.
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Conclusion
CKD is a positively associated with the presence of AAA. In contrast, DM is a negatively
associated with the presence of AAA in Japanese population.
Introduction
Abdominal aortic aneurysm (AAA) is the most popular aortic aneurysm. Previous hospital-
and population-based studies reported that the estimated prevalence of AAA in developed
countries is 4 to 9% [1–6]. Most of AAAs are asymptomatic until rupture. However, once rup-
ture occurs, it mostly leads to a rapid clinical course and results in sudden death. Mortality
rates are as high as 90%, and 50 to 70% cases who were taken in the operating room died [7–9].
The incidence of AAA increases with age, particularly over 60 years old [3, 5, 10]. Since it is
expected that the number of elderly population increases in future, the prevalence of AAA
could increase substantially.
In general, the risk factors for AAA are smoking, male gender, aging, Caucasian race, hyper-
tension and family history of AAA [10–12]. These risk factors often overlap with many of the
classical risk factors for atherosclerosis. Recently, chronic kidney disease (CKD) [13] has been
recognized as one of the risk factors that promotes atherosclerosis as well as cardiovascular dis-
ease (CVD). Both the decline of glomerular filtration rate (GFR) and the increase of urinary
protein excretion are independent risk factors for CVD [13–16]. However, the association
betweenCKD and AAA remains unknown. DiabetesMellitus (DM) is also considered to be
one of the major risk factors for atherosclerosis. However, DM has been reported to exert
favorable effects on the incidence and development of AAA [4, 17–20]. Indeed, a few studies
raised the possible pathophysiological mechanisms of the relationship betweenDM and AAA,
that is, the cross-interaction among the extracellularmatrix, inflammatory cells, the chronic
glucose elevation and advanced glycated end products (AGEs) [21–26]. Since these studies
were conducted in the western population, such a protective role of DM on AAA was not
explored in the Asian population.
The purpose of this study was to clarify the impact of CKD and DM on the presence of
AAA.We performed a cross-sectional retrospective case-control study in Japanese population.
Materials and Methods
Study participants
To examine the relationship of cardiovascular risk factors with the presence of AAA, we retro-
spectively enrolled 261 patients who were diagnosedwith AAA by abdominal computed tomo-
graphic scanning (CT) at the department of Cardiovascular Surgery of Okayama University
hospital and Kure Kyosai hospital between January 2008 and December 2014 as the AAA
+ group. We also enrolled age-and-sex matched 261 patients frommore than ten-thousand
patients who received abdominal CT except at the department of Cardiovascular Surgery as
the control (AAA-) group during same period. Furthermore, in order to investigate the preva-
lence of AAA, we retrospectively enrolled 1126 patients who underwent abdominal CT at the
department of Nephrology as the CKD group and 400 patients who underwent abdominal CT
at the department of Diabetes as the DM group.
CKD and DM with AAA
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Evaluation items and criteria
AAA was defined as the maximum abdominal aortic diameter in minor axis 3.0 cm on CT
in our study [3]. By checkingmedical records, cardiovascular risk factors of each patient were
evaluated: bodymass index (BMI), hypertension (HTN), dyslipidemia (DLP), DM, CKD,
smoking habit, ischemic heart disease (IHD) and stroke. HTN was defined as an office blood
pressure of 140/90 mmHg and above. The patients who took antihypertensive agent were also
considered to have HTN. DLP was defined as the serum concentration of low-density lipopro-
tein cholesterol of 140 mg/dL and above, the serum concentration of high-density lipoprotein
cholesterol of below 40 mg/dL, or the serum concentration of triglyceride of 150 mg/dL and
above. The patients who took anti-lipidemic agent were also considered to have DLP. DM was
defined as the level of HbA1c (NGSP) of 6.5% and above. The patients who took anti-diabetic
agents were regarded to have DM. CKD was defined as the level of estimated GFR (eGFR) [27]
of below 60 mL/min/1.73m2 and/or proteinuria [13]. Proteinuria was defined to be positive in
the urine dip stick examination. Smoking habit were defined as a current or former smoking
habit. IHD was defined as a symptomatic angina pectoris or myocardial infarction that
required the treatment of percutaneous coronary artery intervention or coronary artery bypass
grafting. Stroke was defined as a symptomatic cerebral infarction or hemorrhage.
Ethics
This study followed the Declaration of Helsinki (seventh revision, 2013) on medical protocol
and ethics. This is a retrospective observational study. We corrected the data only from physi-
cian’s chart, therefore our Institutional ReviewBoard waived the requirement of written
informed consent but requested to give the opportunity to the patients to reject the enrollment
of this study by leaflets or website of our hospital. Finally, the ethics committees of Okayama
University Institutional ReviewBoard (accredited ISO9001/2000), Okayama, Japan and Kure
Kyosai hospital Institutional ReviewBoard approved the protocol.
Statistics
All data were expressed as the mean ± standard deviation. Differences betweenAAA+ group
and AAA- group were examined by unpaired t-test or chi-square test. Odds ratio were studied
to evaluate the risk factor for AAA. Multiple logistic regression analysis was carried out to
examine the independent associations among risk factors. A difference of P< 0.05 was taken
as statistically significant. All the data were analyzed using Sigma Stat for Windows (version
3.5, Systat Software Inc., San Jose, California, USA).
Results
Characteristics of Participants
The characteristics of participants were shown in Table 1. The participants of AAA+ group
included 203 of male and 58 of female. Average age of AAA+ group was 77.0 ± 8.3 years old.
The number of subjects, sex ratio and age of AAA- group completely matched AAA+ group.
There were no differences between two groups in BMI and serum creatinine concentration.
eGFR in AAA+ group was significantly lower than that in AAA- group (AAA+; 54.4 ± 21.2
mL/min/1.73m2, AAA-; 61.4 ± 26.2 mL/min/1.73m2, P< 0.001), despite matched age and sex
ratio. However, the level of HbA1c in AAA- group was significantly higher than that in AAA
+ group (AAA+; 5.7 ± 0.6%, AAA-; 5.9 ± 0.9%, P = 0.034).
CKD and DM with AAA
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Presence of risk factors for AAA
As shown in Table 2, the presence of the risk factors in AAA+ group, such as HTN, DLP and
CKD, were significantly higher than that in AAA- group. Whereas, the presence of DM in AAA
+ group was significantly lower than in AAA- group (AAA+; 17%, AAA-; 35%, P< 0.001). No
differences in smoking habit and the history of stroke were observedbetween groups. The pres-
ence of IHD in AAA+ group was 21% higher than in AAA- group (P< 0.001).
Regression analysis
Results of univariate and multivariate logistic regression analysis of factors associated with
AAA were shown in Table 3. HTN, DLP, CKD, smoking habit and the history of IHDwere
positively associated with AAA by a univariate regression analysis. Only DM was negatively
associated with AAA (OR; 0.381, 95%C.I.; 0.252–0.575, P< 0.001). The history of stroke was
not significantly correlated with the presence of AAA. In addition, a multivariate logistic
regression analysis revealed that HTN, CKD and the history of IHDwere independent deter-
minants, whereas, DM was the only independent negative determinant, for the presence of
AAA.
Table 1. Clinical Characteristics of Patients With and Without AAA.
AAA+ (n = 261) AAA- (n = 261) P value
Age, years 77.0 ± 8.3 77.0 ± 8.3
Sex (male), n (%) 203 (78%) 203 (78%)
Height, (cm) 160.6 ± 8.8 159.5 ± 8.4 0.184
Weight, (kg) 58.6 ± 11.8 56.3 ± 11.1 0.025*
Body mass index, (kg/m2) 22.7 ± 3.8 22.1 ± 3.8 0.140
Cr, (mg/dl) 1.28 ± 1.19 1.18 ± 1.27 0.390
eGFR, (ml/min/1.73m2) 54.4 ± 21.2 61.4 ± 26.2 < 0.001**
HbA1c, (%) 5.7 ± 0.6 5.9 ± 0.9 0.034*
Ant-Hypertensive therapy
Angiotensin-receptor blocker 36.2% 34.5%
Angiotensin-converting enzyme inhibitor 20.7% 2.6%
Calcium-channel blocker 41.4% 34.5%
Diuretic 18.1% 8.6%
β-blocker 25.0% 8.6%
Diabetic therapy
Insulin 2.6% 7.8%
Pioglitazone 4.3% 2.6%
Metformin 0% 2.6%
Sulfonylurea 2.6% 6.9%
DPP4-Inhibitor 3.4% 7.8%
Others
Statin 37.9% 17.2%
EPA 0.9% 2.6%
Anti-Platelet therapy 32.8% 15.5%
Data are presented as mean value ± standard deviation or n (%) of patients. AAA, abdominal aortic aneurysm; Cr, creatinine; eGFR, estimated glomerular
filtration rate; Hb, Hemoglobin; DPP, Dipeptidyl Peptidase; EPA, eicosapentaenoic acid. P values are obtained by unpaired student’s t-test.
*P < 0.05
**P < 0.01
doi:10.1371/journal.pone.0164015.t001
CKD and DM with AAA
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Prevalence of AAA in patients with CKD or DM
We next investigated the prevalence of AAA in patients with CKD or DM. Firstly, total 1126
patients (male / female: 612 / 524) with CKDwere examined. Average age of CKD group was
56.4 ± 19.0 years old. The number of patients 55 years old and above, 65 years old and above,
and 75 years old and above were 670 (male / female: 380 / 290), 468 (male / female: 277 / 191)
and 207 (male / female: 116 / 91), respectively (Table 4). The prevalence of AAA in the patients
with CKDwas 2.5% in all patients, 3.9% in patients 55 years old and above, 5.1% in patients 65
years old and above and 7.2% in patients 75 years old and above, respectively.
Secondly, total 400 patients (male / female: 202 / 198) with DM were examined. Average age
of DM group was 58.5 ± 15.9 years old. The number of patients 55 years old and above, 65
years old and above, and 75 years old and above were 271 (male / female: 137 / 134), 167 (male
/ female: 88 / 79) and 56 (male / female: 29 / 27), respectively (Table 4). The prevalence of AAA
Table 2. Prevalence of Risk Factor and Past History.
AAA+ (n = 261) AAA- (n = 261) P value
CKD, n (%) 170 (65%) 136 (52%) 0.004**
DM, n (%) 44 (17%) 91 (35%) < 0.001**
HTN, n (%) 202 (77%) 160 (61%) < 0.001**
DLP, n (%) 132 (51%) 103 (39%) 0.017*
Smoking habit (Current + Former), n (%) 152 (58%) 130 (50%) 0.071
Current smoker, n (%) 44 (17%) 37 (14%)
Former smoker, n (%) 108 (41%) 93 (36%)
Never smoked, n (%) 96 (37%) 116 (44%)
History of IHD, n (%) 85 (33%) 31 (12%) < 0.001**
History of stroke, n (%) 31 (12%) 39 (15%) 0.397
Data are presented as n (%) of patients. AAA, abdominal aortic aneurysm; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; DLP,
dyslipidemia; IHD, ischemic heart disease. P values are obtained by chi-square test.
*P < 0.05
**P < 0.01
doi:10.1371/journal.pone.0164015.t002
Table 3. Univariate and Multivariate Analysis for the Presence of AAA.
Univariate analysis Multivariate analysis model 1 Multivariate analysis model 2
Odds ratio 95% C.I. P value Odds ratio 95% C.I. P value Odds ratio 95% C.I. P value
CKD 1.710 1.197–2.443 0.003** 1.606 1.068–2.417 0.023* 1.603 1.064–2.414 0.024*
DM 0.381 0.252–0.575 < 0.001** 0.306 0.191–0.489 < 0.001** 0.301 0.188–0.482 < 0.001**
HTN 2.237 1.552–3.289 < 0.001** 1.880 1.224–2.889 0.004** 1.874 1.219–2.881 0.004**
DLP 1.554 1.097–2.202 0.013* 1.374 0.920–2.052 0.120 1.367 0.915–2.043 0.127
Smoking habit 1.439 1.015–2.040 0.041* 1.518 0.982–2.347 0.060 1.476 0.951–2.288 0.082
History of IHD 3.683 2.332–5.816 < 0.001** 3.754 2.255–6.250 < 0.001** 3.819 2.289–6.374 < 0.001**
History of Stroke 0.777 0.468–1.290 0.330 0.708 0.400–1.254 0.236
AAA, abdominal aortic aneurysm; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; DLP, dyslipidemia; IHD, ischemic heart disease;
C.I., confidence interval. In Multivariate analysis model 1, adjusted for items that significant difference was out with univariate analysis, age and sex. In
Multivariate analysis model 2, adjusted for all items, age and sex. P values are obtained by multiple logistic regression analysis.
*P < 0.05
**P < 0.01
doi:10.1371/journal.pone.0164015.t003
CKD and DM with AAA
PLOS ONE | DOI:10.1371/journal.pone.0164015 October 20, 2016 5 / 12
in the patients with DM was only 0.5% in all patients, 0.6% in patients 55 years old and above,
0.6% in patients 65 years old and above and 0% in patients 75 years old and above, respectively.
The prevalence of AAA in CKD group tended to increase along with age, while the preva-
lence of AAA in DM group did not. Indeed, the prevalence of AAA in the patients with DM
was very low throughout the ages.
Discussion
This study demonstrated for the first time that CKDwas positively associatedwith the presence
of AAA. In contrast, DM was negatively associated with the presence of AAA in Japanese pop-
ulation. Additionally, it is confirmed that the other risk factors for the presence of AAA in this
study, such as HTN, IHD, DLP and smoking habit, accord consistently with those in western
countries.
Previous screening studies reported that the estimated prevalence of AAA in western coun-
tries is 4 to 9% [1–6]. The prevalence in western countries is higher than that in Asian countries
[28]. The Life Line Screening cohort study also showed a reduced risk for Asian-Americans
(odds ratio 0.72) compared with Caucasian populations [11]. The incidence of AAA in Japa-
nese was about 2.7% based on the data of Japanese autopsy [29]. The AAA Japan study, a large
multicenter cohort study, showed that AAA is present in 4.1% of Japanese patients with HTN
60 year old and above [1]. In this study, the prevalence of AAA in patients with CKD 65 years
old and above was 5.1%, relatively higher than previous two studies. Our study demonstrated
that CKD is associatedwith the presence of AAA. There are a few studies that support our find-
ings. A cohort study conducted at an integrated health care delivery system in northern Cali-
fornia displayed that the renal insufficiency significantly associated with risk of AAA [18]. In a
screening program at a regional Veterans Affairs health system study, Chun KC, et al. identi-
fied renal insufficiencyas a risk factor. They found that eGFR< 60 mL/min/1.73m2 was signif-
icantly associated with AAA (36.7% vs. 24.3%; P< 0.001) [30]. A European group described
that the stage of CKD revealed significant differences betweenAAA patients undergoing elec-
tive open repair surgery and controls [31], and the group also reported that 563 AAA patients
prior to surgical repair contained 35.4% of stage III-V CKD [32]. However, these studies did
not evaluate proteinuria, as an independent factor for AAA in their cohort. In another study,
renal insufficiency significantly increased local levels of MMP-2 [33]. Both in the animal mod-
els and human studies, aortic aneurysm correlated with an increase in aorticMMPs levels such
Table 4. Prevalence of AAA in CKD group or DM group.
CKD group (n = 1126) DM group (n = 400)
Age, years 56.4 ± 19.0 58.5 ± 15.9
Sex (male), n (%) 612 (54.4%) 202 (50.5%)
55 y.o. and above, n (%) 670 (59.5%) 271 (67.8%)
65 y.o. and above, n (%) 468 (41.6%) 167 (41.8%)
75 y.o. and above, n (%) 207 (18.4%) 56 (14.0%)
Prevalence of AAA
All, n (%) 28 (2.5%) 2 (0.5%)
55 y.o. and above, n (%) 26 (3.9%) 2 (0.6%)
65 y.o. and above, n (%) 24 (5.1%) 1 (0.6%)
75 y.o. and above, n (%) 15 (7.2%) 0(0%)
Data are presented as mean value ± standard deviation or n (%) of patients. AAA, abdominal aortic
aneurysm; CKD, chronic kidney disease; DM, diabetes mellitus; y.o., years old.
doi:10.1371/journal.pone.0164015.t004
CKD and DM with AAA
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as MMP-2, -3, -9 and -12 [34–38]. In an animal model, Ziyi Liu, et al. reported an association
between hyperhomocysteinemia (HHcy) and AAA (odds ratio, 7.39) in a meta-analysis, fur-
thermore they observedHHcy aggravates AAA formation via activating adventitial fibroblast
NADPH oxidase 4 in angiotensin II–infusedmale apolipoprotein E deficient mice. [39] Since
CKD is well-known risk factor for atherosclerosis and CVD [13–16], it makes a great deal of
sense that CKD is associated with AAA. In most cases, AAA is accompanied by HTN and ath-
erosclerotic lesions. HTN and atherogenic condition often cause nephrosclerosis. Thus, it is
likely that AAA is often associated with renal dysfunction, that is, CKD. Also, AAA usually
presents at suprarenal, pararenal, or juxtarenal lesion, which is involved with or is located near
the renal arteries. As a result, the blood flow to the renal artery becomes abnormal, and this
blood flow carries cholesterol crystal and mural thrombus from the AAA wall to the renal
artery, resulting in the failure of renal function. Therefore, it is likely that AAA is related with
CKD. On the other hand, if Renin-Angiotensin-System (RAS) inhibitors are administered to
the patients with AAA, these agents exert a protective role on the kidney, especially to reduce
their urinary proteins and blood pressure, leading the improvement of CKD. In our study, as
shown in Table 1, AAA cases had more prevalence of CKD although AAA cases took more
RAS inhibitors than Non-AAA. Accordingly, these findingsmay emphasize the positive associ-
ation betweenAAA and CKD.
DM is well-established risk factor for CVD, and is associated with increased long termmor-
tality of arterial diseases [40–42]. However, a protective effect of DM on AAA was observed in
several studies [4, 43–46]. A previous study revealed the inverse association betweenDM and
aortic dilatation in 351 patients with advanced coronary artery disease in Japanese population
[20]. Furthermore, a German study reported that wall thickness of AAA was increased in DM
patients [47]. In the present study, we revealed that DM was negatively associated with AAA in
Japanese population. Also, the prevalence of AAA in patients with DM 65 years old and above
was 0.6%, clearly lower than the prevalence of AAA in general population of 2.7% [29]. A few
previous studies suggested the potential mechanism of the protective effect of DM on AAA.
Elevated glucose in patients with DM increases glycation of protein precursors resulting in
increased formation of advanced glycation end products (AGEs) [22, 24]. AGE-mediated
cross-links of collagen and elastin in aortic wall, reduces elasticity and increases the arterial
stiffening and resistance to proteolysis by the mechanism reported that glycated matrix impairs
MMP-1 synthesis and MMP-2 activation, and AGEs stimulate collagen synthesis via protein
kinase C and TGF-β1 upregulation [23]. AGEs might increase smooth muscle cell proliferation
and reduce the aneurysmal expansion and rupture [21, 22, 25, 26]. Furthermore, it is reported
that patients with DM have reduced levels of MMP-2 and MMP-9, inhibiting the breakdown
of the extracellularmatrix proteins in the aortic wall [48, 49]. Further study is needed to eluci-
date the precise mechanism how DM prevents AAA.
As is the case in our study, the several risk factors for AAA overlapped with those for ath-
erosclerosis. Indeed, atherosclerotic changes are frequently observed in aortic wall of AAA
patients. The patients with AAA are often associatedwith multiple risk factors for atherosclero-
sis. The TromsøStudy, a population-based study of 6,386 men and women in Tromsø Norway,
indicated that risk factors for atherosclerosis are associated with increased risk for AAA [5].
RodinMB, et al. reported that the major risk factors for atherosclerosis, such as hyperlipidemia,
HTN and smoking habit were positively and independently associated with AAA [50]. Several
studies showed the positive correlation betweenCVD and AAA [18, 30, 51]. A cohort study in
Northern California confirmed that major atherosclerotic risk factors including IHD and arte-
riosclerosis obliterans are related to AAA [18]. Our study also demonstrated that HTN and
IHDwere positively associated with AAA.
CKD and DM with AAA
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Limitation
The present study had several limitations. First, some reports definedAAA as focal dilation of
the abdominal aorta that are 50% greater than the proximal normal segment or that are 3.0
cm. However, we definedAAA as the maximum abdominal aortic diameter in minor
axis 3.0 cm on CT according to ACC/AHA Guideline. Second, this study was retrospective
case-control cross sectional study. Family history, socioeconomic status, histological and
genetic information were not obtained enough to examine, because of lack of data in the physi-
cian’s charts. Third, there was a sampling bias in the present study, since we recruited the hos-
pital-based population who received CT scanning as controls, in order to align the background
of the patients. In addition, as previously described,we accordingly enrolled elderly patients.
Therefore, each group had higher prevalence of DM than general population. Fourth, the defi-
nition of DM in this study was that patients were already diagnosed and using medical treat-
ment or their HbA1c was 6.5% and above. In this retrospective study, there was few data that
could be evaluated constant blood glucose levels. Since blood glucose data were not precisely
assessable, we could not add these data to the analysis. In addition, we did not investigate the
patients with diabetic nephropathy in detail because of the small number of participants. Fifth,
this study included only the Japanese population. The differences among the races were not
examined. Sixth, this study included only two centers’ patients and relatively small number of
patients were examined.
Conclusion
We found that CKD is the independently associated with the presence of AAA, in contrast,
DM is independently and negatively associated with the presence of AAA in Japanese popula-
tion (Fig 1). The other risk factors, such as HTN and IHD, were confirmed as independently
determinants for AAA. Our findings propose the idea that the screening examination by ultra-
sonography for CKD patients may detect AAA in earlier stage, then these patients can be prop-
erly treated to avoid the fatal events. Further large number, prospective studies and basic
research are required to investigate the association and the underlyingmechanisms of AAA
with CKD and DM.
Fig 1. Schema of the relationship among CKD, DM and AAA. CKD is one of the positive determinants, meanwhile, DM is one of the
negative determinants, for AAA presence.
doi:10.1371/journal.pone.0164015.g001
CKD and DM with AAA
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